– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard…
- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with…
Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of 2023 Anticipates receipt in the…
SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging…
Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over…
Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31,…
Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PTNEW YORK, Jan. 06, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics,…
Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral…
WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing…
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital…